WE'RE ON A MISSION TO EXTEND LONGEVITY BY TRANSFORMING HOW THE WORLD TREATS INFLAMMATION

Sen-Jam Pharmaceutical is focused on improving clinical outcomes for patients battling inflammation-based diseases such as viral respiratory infections from coronaviruses such as COVID-19 and other painful inflammation and toxin-induced conditions, including arthritis, vaccinations, opioid withdrawal and even the infamous hangover. Using our patented proprietary technology of “next generation anti-inflammatories” and the accelerated 505(b)2 pathway, we’re addressing the root causes of autoimmune inflammation—much like how Ozempic targets metabolic inflammation.. Our mission: to transform how we treat inflammation and reshape the business of pain relief for the betterment of humanity..

Therapeutic Pipeline

Icon Repurposing

Repurposing

Two Small Molecules

By taking two already proven to be both effective and safe molecular agents and ingenuously combining them, Sen-Jam has discovered a simple yet powerful product that very well may change the way the world views pain relief. Our patent portfolio is rich with global relevancy and our clinical studies, both executed and planned exhibit a modern ingenuity not common to our peers.

Icon Reimagining

Reimagining

Partnerships

Our strategic partnerships run the full developmental spectrum and offer a refreshingly open model for partnerships to thrive and communities to benefit in multiple ways. From licensing to distribution and beyond, we embrace an entrepreneurial can-do spirit to transform the way healthcare connects commerce to caring.

Sen-Jam’s Head of Clinical Development speaking to hundreds of innovators and health transformers at the StartUp Health Festival during JP Morgan’s Health Conference in San Francisco, January 2019

Over 470 Million
people worldwide

have been infected by COVID-19
(as of March 2022)

Icon Coronavirus

Over 6 Million
of them died
The Race to Find a
TREATMENT FOR CORONAVIRUS INFECTIONS

The world was stopped in its tracks by the incredible impact from the global pandemic. The COVID-19 ripple effects brings with it the third and greatest economic, financial and social shock of the 21st century, after 9/11 and the global financial crisis of 2008. And the controversy around vaccines and treatments creates even more chaos than calm. That said, there is a very promising, common sense approach to treating coronavirus infections to help mitigate disease progression that so often harrowingly leads to lung damage. The time is now for a smarter more modern approach to treating this pandemic. We believe and science supports this fact, that the true culprit is runaway inflammation. Let’s tackle this issue once and for all.

Icon Antivirals

The majority of treatments for COVID-19 today are anti-virals which come with

serious side effects
Icon Hospital Bed

The cost for one of the more prominent Big Pharma coronavirus treatments exceeds

$700 per dose

(SJP-002C hopes to be about a tenth of that cost)

Solving for OVERINDULGENCE AND
METABOLIC DYSREGULATION

Since the first feast and the first fermented brew, humans have stretched the limits of consumption—and paid for it the morning after. Whether it’s double helpings of sugar-laden comfort food or rounds of cocktails, overindulgence tips the body into metabolic dysregulation: glucose spikes, gut permeability, toxic by-products, and a surge of inflammatory mediators that leave us foggy, nauseated, thirsty, and fatigued once blood alcohol or insulin levels crash. What we’ve long called a “hangover” is really the body’s alarm that its metabolic balance has been breached. While theories abound, the evidence keeps circling back to sterile inflammation as the common root of both food- and alcohol-induced malaise—the very root Sen-Jam’s Metabolic Recovery program is designed to calm.

Icon Drinks
$1.5 Trillion
global alcohol beverage market

Icon 68 Percent

65% of people
who drink moderate levels of alcohol report
negative symptoms
the next day

Coffee Aspirin

75%
workers
claim they have been
hung over
at work

 

1 out of 2
people worldwide
will be obese or overweight
by 2035
Icon Down Arrow Green
68 Billion Lost

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Icon Pill

Putting an End to

The Opioid Crisis

Opioid Use Disorder is a problematic pattern of opioid use that leads to serious impairment or distress. It includes the use of prescription opoiods, heroin, or a combination of both. The intensity of withdrawal symptoms presents a significant barrier to abstinence and opioid dose reduction. Signs of chemical dependency are present within 5 days of opioid use.

100M
people suffer from chronic pain the U.S.
10-15M
people are prescribed opioids to manage pain
3-5M
people are currently diagnosed with Opioid Use Disorder*
Icon People 25
EVERY 25
overdoses results in
ONE DEATH
Fatalities Continue
230 LIVES LOST EVERY DAY
1.8M overdoses
+ over 30K deaths annually
$2.7T
Estimated single-year economic drag of illicit opioids in 2023
Join us as we help put an end to the deadliest drug overdose crisis in American history
Icon Two Chevrons

A tragedy that has killed more people annually than the AIDS crisis, Vietnam and automobile accidents combined.

The agony of opioid withdrawal is far more debilitating than many realize.

It’s Time to Address This Head-on

Therapeutic Pipeline

Addressing Significant Unmet Needs with a Revolutionary Combination Anti-Inflammatory

Icon Rx  Prescription Strength Relief

Icon Otc  Over the Counter Relief

Discovery
Screening
Preclinical
Phase 1
Phase 2
Phase 3

Upper Respiratory Infections, including COVID

SJP-002C Mild to Moderate URI infection - Oral
SJP-100 Critical-Care Rescue - Injectable

Metabolic Recovery (food and alcohol)

SJP-001 Metabolic Rebalance & Recovery - Oral

Opioid Use Disorder

SJP-005 Opioid Withdrawal - Oral
SJP-006 Opioid Dependence - Oral
SJP-007 Opioid Tolerance - Oral

Vaccination Side-effects

SJP-003 Adverse Effects from Vaccine - Oral

Respiratory Common Cold

SJP-002 Viral Respiratory Infection - Oral

Arthritis

SJP-004 Arthritis - Oral
SJP-101 Arthritis - Injectable

Premature Aging

SJP-200 Low-grade Chronic Inflammation - Oral

Icon Rx  Prescription Strength Relief

Icon Otc  Over the Counter Relief

COVID-19/URI
SJP-002C SARS-CoV-2-Mild to Moderate infection - Oral
PHASE 2
SJP-100 SARS-CoV-2-Severe infection - Injectable
PRECLINICAL
Adverse Effects of Alcohol
SJP-001 Alcohol Hangover Prevention - Oral
PHASE 1 END
OPIOID USE DISORDER
SJP-005 Opioid Withdrawal - Oral
PHASE 1 END
SJP-006 Opioid Dependence - Oral
Preclinical
SJP-007 Opioid Tolerance - Oral
Preclinical
VACCINATION SIDE-EFFECTS
SJP-003 Adverse Effects from Vaccine - Oral
Preclinical
UPPER RESPIRATORY INFECTIONS
SJP-002 Viral Respiratory Infection - Oral
PHASE 1
ARTHRITIS
SJP-004 Arthritis - Oral
Preclinical
SJP-101 Opioid Withdrawal - Injectable
Preclinical
Premature Aging
SJP-200 Low-grade Chronic Inflammation - Oral
Preclinical
INVEST NOW

Join Our Mailing List

Stay Connected and Learn How to Help

Sen-Jam Pharmacuetical

Send Us a Message

223 Wall Street #130 • Huntington, NY 11743

Facebook-f X-twitter Linkedin-in Instagram

© 2025 Sen-Jam Pharmaceutical

Therapeutic Pipeline

Icon Rx WhitePrescription Strength

SJP-002C Treatment for SARSCoV-2 Infection

Development: IN PHASE II CLINICAL TRIALS

We believe SJP-002C offers the world the most potent, orally available anti-inflammatory a person could obtain for a mild to moderate coronavirus infection. Since SARS-CoV-2 emerged in 2019, there’s been a frenzy of scientific research on many fronts to help us understand and deal with this virus.

While the Big Pharma giants have been touting the value of anti-virals, we believe the true culprit in regards to tackling a coronavirus infection is the runaway inflammation that results in disease progression (hospitalization) and ultimately organ damage (lung problems we so often see). Antiinflammatory drugs, including NSAIDS—non-steroidal anti-inflammatories—and antihistamines and our combination of these already proven safe agents holds the key to this kingdom. These small molecules, which have already been cleared as safe, can be very effective at calming certain, very reactive parts of the immune system while leaving other parts free to work. That means anti-inflammatories can be offered to more people with less risk than other post-exposure strategies.

International scientists agreed with our premise and wanted to partner with us in our phase II clinical trials, which we are currently engaged in. With these efforts, we are now free to explore their ability to reduce mild-to-moderate symptoms as well as the frequency of progression to severe cases. We are also interested in their ability to prevent long COVID symptoms from occurring, as we explore the relationship between long COVID and inflammation in the brain.

Therapeutic Pipeline

Icon Otc WhiteOver the Counter

SJP-001 Prevention of Veisalgia (Alcohol Hangover)

Development: Phase 1

A hangover is a group of unpleasant signs and symptoms that can develop after drinking alcohol. As if feeling awful weren’t bad enough, frequent hangovers are also associated with poor performance and conflict at work. In fact studies show that there are over a hundred billion dollars lost in productivity as a result of alcohol hangover every year in America.

As a general rule, the more alcohol you drink, the more likely you are to have a hangover the next day. But there’s no magic formula to tell you how much you can safely drink and still avoid a hangover. SJP-001 was designed to help not only treat the signs and symptoms of alcohol hangover, it actually prevents them to begin with. In human studies, SJP-001 has been shown to be effective and safe and is on the pathway to becoming the only FDA-approved agent for this ailment that has hindered societies for thousands of years.

Therapeutic Pipeline

Icon Otc WhiteOver the Counter

SJP-002 Symptoms Associated with Viral Respiratory Infections (including Coronaviruses)

Development: Preclinical

We believe SJP-002 offers the world the most potent, orally available anti-inflammatory a person could obtain OTC. Common colds and viral infections cause irritation and inflammation leading to excessive congestion, coughing, sneezing and headache. By reducing this excessive response, an individual can avoid sick days.

Coronaviruses are a family of viruses that can cause illnesses such as the common cold, severe  acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). In 2019, a  new coronavirus was identified as the cause of a disease outbreak that originated in China; known now as COVID-19.

Recalibrated to prescription strength, we believe SJP-002 could be utilized for the COVID-19 virus. We are in active clinical relationships and are extremely optimistic with early results.

Therapeutic Pipeline

OTC WhiteOver the Counter

SJP-003 Vaccine Administration

Development: Preclinical

Vaccination is the administration of a vaccine to help the immune system develop protection from a disease. Vaccines contain a microorganism or virus in a weakened, live or killed state, or proteins or toxins from the organism. In stimulating the body’s adaptive immunity, they help prevent sickness from an infectious disease.

It is well documented that any vaccine can cause side effects. For the most part these are minor (for example, a sore arm or low-grade fever) and go away within a few days. That said, however, solving for the unintended negative impact vaccinations have on people is available through the proprietary formulation found within SJP-003. When administered at the time of the vaccine shot, signs and symptoms are reduced or eliminated completely.

Therapeutic Pipeline

OTC WhiteOver the Counter

SJP-004 Arthritis

Development: Preclinical

Arthritis is an inflammation of the joints. It can affect one joint or multiple joints. There are more than 100 different types of arthritis, with different causes and treatment methods. Two of the most common types are osteoarthritis (OA) and rheumatoid arthritis (RA). The symptoms of arthritis usually develop over time, but they may also appear suddenly. Arthritis is most commonly seen in adults over the age of 65, but it can also develop in children, teens, and younger adults. Arthritis is more common in women than men and in people who are overweight.

Some of the most common symptoms involved with arthritis include swelling, joint pain and stiffness. Often range of motion will decrease as well as redness of the skin around the joint. Many people with arthritis notice their symptoms are worse in the morning. In order to solve for these painful, often debilitating symptoms, you need a pain reliever that doesn’t create additional problems down the line, like is often the case with opioid-based agents. SJP-004 is designed to help solve for the inflammation and aches involved with arthritis in a meaningfully safe manner. This helps millions of people rebound from the impact of Arthritis and experience a full strength vital lifestyle

Therapeutic Pipeline

Icon Rx WhitePrescription Strength

SJP-006 Opioid Dependence

Development: Preclinical

Opioid use disorder is the chronic use of opioids that causes clinically significant distress or impairment. Opioid use disorders affect over 16 million people worldwide, over 2.1 million in the United States, and there are over 120,000 deaths worldwide annually attributed to opioids. There are as many patients using opioids regularly as there are patients diagnosed with obsessive-compulsive disorder, psoriatic arthritis, and epilepsy in the United States. Opioid use disorder diagnosis is based on the American Psychiatric Association DSM-5 and includes a desire to obtain and take opioids despite social and professional consequences. Examples of opioids include heroin, morphine, codeine, fentanyl, and synthetic opioids such as oxycodone. Opioid use disorder consists of an overpowering desire to use opioids, increased opioid tolerance, and withdrawal syndrome when discontinued. Opioid use disorder includes dependence and addiction with addiction representing the most severe form of the disorder. The disease is harrowing for millions due to the physiological dependence the drug has on the person who takes it. Studies show within just a few days, someone taking opioids exhibits signs and symptoms of dependence. Mitigating dependence is one of the critical factors in turning the tides on the Opioid Epidemic. Our product has shown promising results in all three of the lock holds Opioids have on people who use them: Dependence, Tolerance and Withdrawal.

SJP-006 is designed to specifically address opioid dependence and by doing so, makes tapering off opioid pain killers a more readily available option to the millions who are prescribed opioids each year. This prevents massive destruction in terms of prolonged addiction, jeopardizing professional and personal lives and in some cases, leading to death.

Therapeutic Pipeline

Icon Rx WhitePrescription Strength

SJP-005 Opioid Withdrawal

Development: Preclinical

Opioid use disorder is the chronic use of opioids that causes clinically significant distress or impairment. Opioid use disorders affect over 16 million people worldwide, over 2.1 million in the United States, and there are over 120,000 deaths worldwide annually attributed to opioids. There are as many patients using opioids regularly as there are patients diagnosed with obsessive-compulsive disorder, psoriatic arthritis, and epilepsy in the United States. Opioid use disorder diagnosis is based on the American Psychiatric Association DSM-5 and includes a desire to obtain and take opioids despite social and professional consequences. Examples of opioids include heroin, morphine, codeine, fentanyl, and synthetic opioids such as oxycodone. Opioid use disorder consists of an overpowering desire to use opioids, increased opioid tolerance, and withdrawal syndrome when discontinued. Opioid use disorder includes dependence and addiction with addiction representing the most severe form of the disorder. One of the key factors that keep millions of people addicted to opioids is the fact that tapering and attempting to stop taking opioids is extremely challenging due to the harrowing impact of signs and symptoms involved with opioid withdrawal on the body. Mitigating withdrawal symptoms is one of the – if not the most important– critical factors in turning the tides on the Opioid Epidemic. Our product, SJP-005 has shown results in our pre-clinical studies to reduce signs and symptoms of withdrawal by 50%. This is a remarkable statistic, worthy of serious installation in the medical community to help combat the Opioid Crisis.

Therapeutic Pipeline

Icon Rx WhitePrescription Strength

SJP-007 Opioid Tolerance

Development: Preclinical

Opioid use disorder is the chronic use of opioids that causes clinically significant distress or impairment. Opioid use disorders affect over 16 million people worldwide, over 2.1 million in the United States, and there are over 120,000 deaths worldwide annually attributed to opioids. There are as many patients using opioids regularly as there are patients diagnosed with obsessive-compulsive disorder, psoriatic arthritis, and epilepsy in the United States. Opioid use disorder diagnosis is based on the American Psychiatric Association DSM-5 and includes a desire to obtain and take opioids despite social and professional consequences. Examples of opioids include heroin, morphine, codeine, fentanyl, and synthetic opioids such as oxycodone. Opioid use disorder consists of an overpowering desire to use opioids, increased opioid tolerance, and withdrawal syndrome when discontinued. Opioid use disorder includes dependence and addiction with addiction representing the most severe form of the disorder. The disease is harrowing for millions due to the physiological dependence the drug has on the person who takes it.

Opioid dependence paralyzes so many in the world is the fact that as your body physiologically becomes more and more reliant on an opioid to achieve pain relief, over time, the body requires higher doses of an opioid agent to obtain the same level of relief. This is referred to has Opioid Tolerance. We believe our product, SJP-007, helps lower individual tolerance factors to opioids, including OxyContin, morphine, oxycodone, opium, Vicodin, Demerol, hydrocodone, methadone, Suboxone, heroin, and tramadol. By lowering tolerance factors involved with opioid use disorder, more people can reverse the hold opioids have on their lives.

Leaving so soon?

Join us in revolutionizing how the world treats inflammation. Stay informed about our latest breakthroughs in pain relief, viral infections, and opioid withdrawal.